Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

About Arena Pharmaceuticals

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARNA
  • CUSIP: 04004710
Key Metrics:
  • Previous Close: $1.47
  • 50 Day Moving Average: $1.47
  • 200 Day Moving Average: $1.56
  • 52-Week Range: $1.34 - $2.16
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.32
  • P/E Growth: 0.22
  • Market Cap: $357.67M
  • Outstanding Shares: 243,313,000
  • Beta: -0.64
Profitability:
  • Net Margins: -197.50%
  • Return on Equity: -336.85%
  • Return on Assets: -39.53%
Debt:
  • Debt-to-Equity Ratio: 15.40%
  • Current Ratio: 2.23%
  • Quick Ratio: 2.06%
Additional Links:
Companies Related to Arena Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Arena Pharmaceuticals (NASDAQ:ARNA) (?)
Ratings Breakdown: 4 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $3.75 (155.10% upside)

Analysts' Ratings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Show:
DateFirmActionRatingPrice TargetDetails
1/23/2017FBR & CoReiterated RatingOutperformView Rating Details
1/7/2017Needham & Company LLCReiterated RatingHoldView Rating Details
8/10/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
8/8/2016J P Morgan Chase & CoReiterated RatingHoldView Rating Details
5/10/2016Wells Fargo & CompanyReiterated RatingHoldView Rating Details
3/2/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
3/1/2016Royal Bank of CanadaReiterated RatingSector Perform$2.00 -> $1.50View Rating Details
10/28/2015WallachBeth CapitalLower Price TargetBuy$6.00 -> $4.00View Rating Details
5/14/2015BMO Capital MarketsReiterated RatingMarket Perform$9.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Arena Pharmaceuticals (NASDAQ:ARNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017($0.08)N/AView Earnings Details
11/7/2016Q316($0.07)($0.05)$13.99 million$19.20 millionViewN/AView Earnings Details
8/8/2016Q216($0.10)($0.11)$10.44 million$9.50 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.09)$9.02 million$9.80 millionViewN/AView Earnings Details
2/29/2016Q415($0.13)($0.13)$8.26 million$7.80 millionViewN/AView Earnings Details
11/10/2015Q315($0.13)($0.11)$8.87 million$9.10 millionViewN/AView Earnings Details
8/5/2015Q215($0.14)($0.11)$10.95 million$9.18 millionViewN/AView Earnings Details
5/11/2015Q115($0.14)($0.10)$10.56 million$12.30 millionViewN/AView Earnings Details
3/2/2015Q414($0.12)($0.15)$10.36 million$9.20 millionViewN/AView Earnings Details
11/3/2014Q314($0.12)($0.05)$10.90 million$8.20 millionViewN/AView Earnings Details
8/1/2014Q2 14($0.11)$0.03$9.81 million$12.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.10)($0.12)$7.98 million$6.80 millionViewN/AView Earnings Details
2/27/2014Q413$0.02($0.11)$7.00 million$6.50 millionViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$5.30 million$3.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.15$0.18$57.30 million$68.90 millionViewN/AView Earnings Details
4/30/2013Q1 2013$0.11$0.09$50.36 million$2.37 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.03)($0.10)$21.94 million$1.94 millionViewN/AView Earnings Details
11/6/2012Q312($0.11)($0.07)$3.72 million$1.50 millionViewN/AView Earnings Details
8/9/2012($0.08)($0.12)ViewN/AView Earnings Details
11/9/2011($0.14)($0.16)ViewN/AView Earnings Details
8/9/2011($0.15)($0.16)ViewN/AView Earnings Details
5/10/2011($0.21)($0.35)ViewN/AView Earnings Details
3/11/2011($0.22)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arena Pharmaceuticals (NASDAQ:ARNA)
Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.34 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.07)($0.07)($0.07)
Q4 20161($0.07)($0.07)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arena Pharmaceuticals (NASDAQ:ARNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Arena Pharmaceuticals (NASDAQ:ARNA)
Insider Ownership Percentage: 2.14%
Institutional Ownership Percentage: 48.99%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.72View SEC Filing  
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.00View SEC Filing  
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.00View SEC Filing  
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.00View SEC Filing  
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.25View SEC Filing  
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.00View SEC Filing  
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00View SEC Filing  
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00View SEC Filing  
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00View SEC Filing  
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Arena Pharmaceuticals (NASDAQ:ARNA)
DateHeadline
News IconTrading Corner: Eye on Technical Levels for Arena Pharmaceuticals Inc (ARNA) - The Standard (NASDAQ:ARNA)
6milestandard.com - February 24 at 1:14 PM
News IconArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Pushing Higher Before Market Open - Aiken Advocate (NASDAQ:ARNA)
aikenadvocate.com - February 24 at 1:14 PM
News IconThe Technicals For Arena Pharmaceuticals, Inc. (ARNA) Have Been Dissected (Brutally) - NY Stock News (NASDAQ:ARNA)
nystocknews.com - February 24 at 1:14 PM
News IconFiscal Year Earnings Estimate on Arena Pharmaceuticals, Inc.(ARNA) - Money Flow Index & Trends (NASDAQ:ARNA)
www.moneyflowtrends.com - February 23 at 3:39 PM
News IconLooking Ahead for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:ARNA)
aikenadvocate.com - February 23 at 1:51 AM
News IconABR Of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Stock At 2 - Stock Observer (NASDAQ:ARNA)
www.thestockobserver.com - February 23 at 1:51 AM
News IconInteresting ARNA Call Options For October 20th (NASDAQ:ARNA)
www.stockoptionschannel.com - February 22 at 8:38 PM
News IconMomentum Watch on Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Midway Monitor (NASDAQ:ARNA)
midwaymonitor.com - February 22 at 3:38 PM
thestreet.com logoInteresting ARNA Call Options For October 20th - TheStreet.com (NASDAQ:ARNA)
www.thestreet.com - February 22 at 3:37 PM
capitalcube.com logoArena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : February 22, 2017 (NASDAQ:ARNA)
www.capitalcube.com - February 22 at 11:24 AM
News IconAnalysts Peer Into Their Crystal Balls For Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Where Is It headed? - Winfield Review (NASDAQ:ARNA)
winfieldreview.com - February 21 at 8:59 AM
News IconA Technical Look At 2 Stocks: Arena Pharmaceuticals, Inc. (ARNA), Bloomin' Brands, Inc. (BLMN) - Post Analyst (NASDAQ:ARNA)
postanalyst.com - February 18 at 3:35 PM
schaeffersresearch.com logo2 Cheap Small-Cap Stocks With Room to Run (NASDAQ:ARNA)
www.schaeffersresearch.com - February 16 at 8:45 PM
marketexclusive.com logoArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Files An 8-K Departure of Directors or Certain Officers; Election of ... - Market Exclusive (NASDAQ:ARNA)
marketexclusive.com - February 16 at 8:34 AM
finance.yahoo.com logoArena Pharmaceuticals Appoints Three New Members to Board of Directors (NASDAQ:ARNA)
finance.yahoo.com - February 14 at 4:16 PM
biz.yahoo.com logoARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ARNA)
biz.yahoo.com - February 14 at 4:16 PM
News IconForward Earnings Estimate of Arena Pharmaceuticals, Inc.(ARNA) - Highland Mirror (NASDAQ:ARNA)
www.highlandmirror.com - February 11 at 3:36 PM
finance.yahoo.com logoArena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017 (NASDAQ:ARNA)
finance.yahoo.com - February 9 at 3:44 PM
istreetwire.com logo3 Trending Stocks: W&T Offshore, Inc. (WTI), Arena Pharmaceuticals, Inc. (ARNA), Palatin Technologies, Inc. (PTN) - iStreetWire (NASDAQ:ARNA)
istreetwire.com - February 8 at 3:52 PM
News IconWatching Technical Levels on Shares of Arena Pharmaceuticals Inc. (ARNA) - Rives Journal (NASDAQ:ARNA)
rivesjournal.com - February 7 at 9:34 PM
News IconArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Stock ABR At 2 - Stock Observer (NASDAQ:ARNA)
www.thestockobserver.com - February 1 at 3:45 PM
News IconEarnings Forecast Research on Arena Pharmaceuticals, Inc. (ARNA) - Highland Mirror (NASDAQ:ARNA)
www.highlandmirror.com - February 1 at 3:45 PM
News IconShares of ARIAD Pharmaceuticals, Inc. (ARIA) Sees Large Outflow of Money (NASDAQ:ARNA)
larampadinapoli.com - January 31 at 3:49 PM
News IconWatching Technical Levels on Shares of Arena Pharmaceuticals Inc. (ARNA) - Sherwood Daily (NASDAQ:ARNA)
sherwooddaily.com - January 30 at 4:39 PM
News IconArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Projected EPS At $-0.09 - Stock Observer (NASDAQ:ARNA)
www.thestockobserver.com - January 30 at 4:39 PM
capitalcube.com logoArena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 30, 2017 (NASDAQ:ARNA)
www.capitalcube.com - January 30 at 4:39 PM
News IconMarket Focus – Tracking These Shares: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Gilbert Daily (NASDAQ:ARNA)
gilbertdaily.com - January 29 at 8:36 PM
News IconWatching Technical Positions on Arena Pharmaceuticals Inc. (ARNA) - Sherwood Daily (NASDAQ:ARNA)
sherwooddaily.com - January 27 at 9:33 PM
News IconInvestor Corner: Checking in on Shares of Arena Pharmaceuticals Inc. (ARNA) - Sherwood Daily (NASDAQ:ARNA)
sherwooddaily.com - January 26 at 3:56 PM
News IconEarnings in Full Force, Analysts Take Aim at Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Wall Street Beacon (NASDAQ:ARNA)
wsbeacon.com - January 25 at 3:43 PM
istreetwire.com logoStocks in Focus: Zoetis Inc. (ZTS), Arena Pharmaceuticals, Inc. (ARNA), EP Energy Corporation (EPE) - iStreetWire (NASDAQ:ARNA)
istreetwire.com - January 25 at 3:43 PM
News IconTechnical Indicator Review on Shares of Arena Pharmaceuticals Inc. (ARNA) - Sherwood Daily (NASDAQ:ARNA)
sherwooddaily.com - January 24 at 4:06 PM
News IconArena Pharmaceuticals, Inc. (NASDAQ:ARNA) EPS Analysis - The Newburgh Press (NASDAQ:ARNA)
newburghpress.com - January 24 at 4:06 PM
News IconArena Pharmaceuticals Inc ARNA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ARNA)
www.bioportfolio.com - January 19 at 4:42 PM
istreetwire.com logoMomentum Stocks: SLM Corporation (SLM), Arena Pharmaceuticals, Inc. (ARNA), Emerson Electric Co. (EMR) - iStreetWire (NASDAQ:ARNA)
istreetwire.com - January 19 at 2:16 AM
News IconUnder the Microscope We Place Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Prospect Journal (NASDAQ:ARNA)
prospectjournal.com - January 17 at 9:21 PM
4-traders.com logoArena Pharmaceuticals : Technical Reports on Biotech Stocks -- ContraVir Pharma, Arena Pharma, Neuralstem, and CTI BioPharma (NASDAQ:ARNA)
www.4-traders.com - January 17 at 4:20 PM
News IconArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Projected to Achieve ... - Stock Observer (NASDAQ:ARNA)
www.thestockobserver.com - January 17 at 9:56 AM
seekingalpha.com logoArena Pharmaceuticals (ARNA) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:ARNA)
seekingalpha.com - January 13 at 9:08 PM
istreetwire.com logoEye Catching Stocks: Arena Pharmaceuticals, Inc. (ARNA), Rice Energy Inc. (RICE), Xcel Energy Inc. (XEL) - iStreetWire (NASDAQ:ARNA)
istreetwire.com - January 13 at 4:06 PM
fool.com logoWhy Arena Pharmaceuticals Stock Sank in 2016 (NASDAQ:ARNA)
www.fool.com - January 13 at 8:25 AM
News IconIs this Stock Under $5 a Bargain: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Prospect Journal (NASDAQ:ARNA)
prospectjournal.com - January 11 at 8:58 PM
News IconNotable Stock For Under $5: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Prospect Journal (NASDAQ:ARNA)
prospectjournal.com - January 9 at 3:55 PM
marketexclusive.com logoArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Files An 8-K Results of Operations and Financial Condition - Market Exclusive (NASDAQ:ARNA)
marketexclusive.com - January 9 at 1:04 AM
biz.yahoo.com logoARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure (NASDAQ:ARNA)
biz.yahoo.com - January 6 at 8:46 PM
News IconTaking Aim at Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Prospect Journal (NASDAQ:ARNA)
prospectjournal.com - January 6 at 3:44 PM
investopedia.com logoArena Pharma Loses Weight, Dumps Belviq (ARNA) - Investopedia (NASDAQ:ARNA)
www.investopedia.com - January 6 at 3:44 PM
investopedia.com logoArena Pharmaceuticals Dumps Belviq Weight Loss Drug (NASDAQ:ARNA)
www.investopedia.com - January 6 at 3:44 PM
capitalcube.com logoArena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 5, 2017 (NASDAQ:ARNA)
us.rd.yahoo.com - January 5 at 8:57 PM
smarteranalyst.com logoCompany Update (NASDAQ:ARNA): Arena Pharmaceuticals, Inc. and Eisai Amend Marketing and Supply Agreement ... - Smarter Analyst (NASDAQ:ARNA)
www.smarteranalyst.com - January 5 at 3:54 PM

Social

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Where is Arena Pharmaceuticals' stock going? Where will Arena Pharmaceuticals' stock price be in 2017?

7 brokers have issued twelve-month price objectives for Arena Pharmaceuticals' stock. Their forecasts range from $1.50 to $6.00. On average, they anticipate Arena Pharmaceuticals' stock price to reach $3.75 in the next twelve months.

When will Arena Pharmaceuticals announce their earnings?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:

  • According to Zacks Investment Research, "Arena received a boost with the launch of Belviq XR, a once-daily, extended-release formulation of its only marketed drug, Belviq, in October. However, sales of Belviq have been lackluster so far and are yet to pick up significantly. We are encouraged by the company’s decision to shift its priorities to its proprietary clinical-stage pipeline. Notably, Arena’s pipeline consists of early-to-mid stage candidates which are still several years from commercialization. Moreover, competition remains intense in the obesity market which has both branded and generic players.  Arena’s share price has also underperformed the industry in last three months. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (1/25/2017)

  • FBR & Co analysts commented, "We are initiating coverage of Arena Pharmaceuticals, Inc. (ARNA) with an Outperform rating and a 12-month price target of $6 per share. Historically, ARNA focused on obesity with its one approved drug, Belviq (lorcaserin). However, given the company’s expertise in discovery and drug development targeting G protein- coupled receptors (GPCRs), it is now primarily focused on advancing the pipeline with (1) etrasimod (APD334), a S1P receptor modulator for the potential treatment of ulcerative colitis (UC); (2) ralinepag, a prostacyclin receptor (PGI2) agonist for the potential treatment of pulmonary arterial hypertension (PAH); and (3) APD371, a cannabinoid receptor 2 (CB2) agonist in development for GI pain associated with Crohn’s disease." (9/15/2016)

Who owns Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock, Inc (7.80%), Renaissance Technologies LLC (3.09%), State Street Corp (2.56%), FMR LLC (2.46%), Senzar Asset Management LLC (0.77%) and Oxford Asset Management (0.28%). Company insiders that own Arena Pharmaceuticals stock include Christine Anna White, Randall E Woods and Steven W Spector.

Who sold Arena Pharmaceuticals stock? Who is selling Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Metropolitan Life Insurance Co. NY.

Who bought Arena Pharmaceuticals stock? Who is buying Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Renaissance Technologies LLC, Oxford Asset Management, State Street Corp, A.R.T. Advisors LLC and Tudor Investment Corp Et Al.

How do I buy Arena Pharmaceuticals stock?

Shares of Arena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Arena Pharmaceuticals stock cost?

One share of Arena Pharmaceuticals stock can currently be purchased for approximately $1.47.

Arena Pharmaceuticals (NASDAQ:ARNA) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Earnings History Chart

Earnings by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Dividend History Chart

Dividend Payments by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Last Updated on 2/24/2017 by MarketBeat.com Staff